ABVC BioPharma (NASDAQ:ABVC – Get Free Report) and Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.
Analyst Recommendations
This is a summary of current ratings and recommmendations for ABVC BioPharma and Eton Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ABVC BioPharma | 1 | 0 | 0 | 0 | 1.00 |
| Eton Pharmaceuticals | 0 | 1 | 4 | 1 | 3.00 |
Eton Pharmaceuticals has a consensus target price of $71.50, suggesting a potential upside of 43.00%. Given Eton Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than ABVC BioPharma.
Insider & Institutional Ownership
11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares ABVC BioPharma and Eton Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ABVC BioPharma | N/A | -47.68% | -30.97% |
| Eton Pharmaceuticals | 12.02% | 40.13% | 12.37% |
Risk and Volatility
ABVC BioPharma has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
Earnings and Valuation
This table compares ABVC BioPharma and Eton Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ABVC BioPharma | N/A | N/A | -$7.91 million | ($0.30) | -3.47 |
| Eton Pharmaceuticals | $105.59 million | 13.53 | -$4.60 million | $0.38 | 131.58 |
Eton Pharmaceuticals has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Eton Pharmaceuticals beats ABVC BioPharma on 13 of the 14 factors compared between the two stocks.
About ABVC BioPharma
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
